Evidence map›Paper›PMID 41130534›Full record

ArticleNeuroImage2025

Aging as an active player in Alzheimer's disease classification: Insights from feature selection in BrainAge models.

Jorge Garcia Condado, Ines Verdugo Recuero, Iñigo Tellaetxe-Elorriaga, Colin Birkhenbil, Maria Carrigan, Ibai Diez, Rachel F Buckley, Asier Erramuzpe, Jesus M Cortes, Alzheimer’s Disease Neuroimaging Initiative

Erratum issuedAbstract read
In one paragraph

Article in NeuroImage, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Jorge Garcia CondadoComputational Neuroimaging Lab, Biobizkaia Health Research Institute, Barakaldo, 48903, Spain; Biomedical Research Doctorate Program, University of the Basque Country, Leioa, 48940, Spain; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Ines Verdugo RecueroDepartment of Signal Processing and Communications, University Carlos III of Madrid, Leganes, 28911, Spain.
Iñigo Tellaetxe-ElorriagaComputational Neuroimaging Lab, Biobizkaia Health Research Institute, Barakaldo, 48903, Spain; Biomedical Research Doctorate Program, University of the Basque Country, Leioa, 48940, Spain.
Colin BirkhenbilDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Maria CarriganDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA; Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam UMC location VUmc, Amsterdam, the Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands; Faculty of Science, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the Netherlands.
Ibai DiezComputational Neuroimaging Lab, Biobizkaia Health Research Institute, Barakaldo, 48903, Spain; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA; IKERBASQUE, the Basque Foundation for Science, Bilbao, 48009, Spain.
Rachel F BuckleyDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA; Center for Alzheimer's Research and Treatment, Brigham & Women's Hospital, HMS, Boston, USA; Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, VIC, 3010, Australia.
Asier ErramuzpeComputational Neuroimaging Lab, Biobizkaia Health Research Institute, Barakaldo, 48903, Spain; IKERBASQUE, the Basque Foundation for Science, Bilbao, 48009, Spain.
Jesus M CortesComputational Neuroimaging Lab, Biobizkaia Health Research Institute, Barakaldo, 48903, Spain; IKERBASQUE, the Basque Foundation for Science, Bilbao, 48009, Spain; Department of Cell Biology and Histology, University of the Basque Country, Leioa, 48940, Spain. Electronic address: jesus.m.cortes@gmail.com.
Alzheimer’s Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Building predictive algorithms to identify resilience and resistance to Alzheimer's diseaseR01AG079142 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Michael C Donohue · 2023 to 2026
$4.0M
NIA NIH HHS R01 AG079142NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundBrainAge models estimate the biological age of the brain using neuroimaging or clinical features, making them promising tools for studying neurodegenerative diseases like Alzheimer's disease. However, the reliance of BrainAge models on neuroimaging features such as grey matter volume and hippocampal atrophy, can introduce biases linked to individuals' ages as these features are influenced both by normal aging and Alzheimer's disease progression. The potential presence of such age-biases raises a critical question: can BrainAge models trained to estimate biological brain aging make meaningful contributions to Alzheimer's diagnosis, or does any introduced age-bias conflate aging effects with disease pathology? Understanding how deliberate feature selection impacts this confounding effect is essential for developing reliable age-related biomarkers. METHODOLOGY: We ranked neuroimaging and neuropsychological features based on their mutual information with age and their discriminative power across five clinical groups: cognitively normal, Mild Cognitive Impairment, Alzheimer's Disease, stable Mild Cognitive Impairment and progressive Mild Cognitive Impairment. Iteratively, we trained BrainAge models using different subsets of these features, some optimized for predicting aging and others for discrimination of clinical Alzheimer's disease stages. We assess the error in BrainAge delta, the difference between predicted biological age and chronological age, and evaluate its classification performance across clinical groups. Finally, we compare using deltas for classification with a logistic regression model directly trained on the neuroimaging features used in the BrainAge models.

resultsNeuroimaging features are more strongly correlated with aging, while neuropsychological features exhibit greater discriminative power for Alzheimer's disease classification. BrainAge models optimized for age prediction yield deltas that are suboptimal when used for classifying Alzheimer´s disease, whereas models trained to generate deltas optimized to be used for classifying Alzheimer's disease have reduced age prediction accuracy. This trade-off suggests that BrainAge models may not optimally separate aging-related changes from disease-specific alterations. BrainAge models have varying classification accuracy as compared to direct utilization of features in logistic regression. However, BrainAge provides a continuous measure, offering a single output that can be used across clinical stages, in contrast to classification approaches that require explicit labels for each disease stage.

conclusionAging significantly affects BrainAge-based classification of Alzheimer's disease. Feature selection plays a critical role in mitigating this effect, as the outputs of models trained to predict age, the deltas, may fail in Alzheimer´s disease classification. These findings underscore the need for task-specific feature selection and model design to ensure that BrainAge models are appropriately applied in neurodegenerative disease research.

Indexed as

AgingAlzheimer DiseaseBrainCognitive DysfunctionModels, NeurologicalNeuroimagingAgedAged, 80 and overFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedAlzheimer’s DiseaseBrain ageMachine LearningNeuroimagingNeuropsychology

Identifiers

PMID41130534
PMCPMC12811041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.